Beta Bionics Wins FDA Clearance for Mint Patch Pump

Beta Bionics has won FDA clearance for Mint, a tubeless insulin patch pump built around a reusable-and-disposable architecture that never needs recharging. The Irvine, California company announced the clearance on 14 September 2026 alongside a 510(k) submission for 3D Intelligence, the next generation of the dosing algorithm that runs its iLet Bionic Pancreas — and set a full U.S. launch for the first quarter of 2027.

From a Boston lab to a second cleared pump

The road from Boston University

1. October 2015

   Beta Bionics founded

   Incorporated as a Massachusetts public benefit corporation to commercialise the bionic pancreas developed in Ed Damiano’s lab at Boston University.

2. May 2023

   iLet Bionic Pancreas cleared

   FDA 510(k) clearance for the first automated insulin delivery system that requires no carb counting; U.S. sales began in June 2023.

3. January 2025

   Nasdaq listing

   Initial public offering under the ticker BBNX.

4. July 2026

   Second-quarter results

   Net sales of $32 million, up 38%; gross margin 59%; about $225 million in cash and investments.

5. 14 September 2026

   Mint cleared; 3D Intelligence submitted

   FDA 510(k) clearance for the Mint patch pump, and a 510(k) filed the same day for the next-generation dosing algorithm.

6. End of 2026

   iLet 3D targeted

   Subject to FDA clearance of 3D Intelligence.

7. Q1 2027

   Mint full U.S. launch

   Pharmacy channel only, with at least 1.5 million disposable units of 2027 capacity.

What FDA cleared, and what it did not

The clearance makes Beta Bionics the second company to bring a tubeless patch pump to the U.S. market, a category Insulet has held alone with Omnipod. According to the company’s announcement, Mint is a two-piece system: a reusable component and a disposable patch worn for three days plus a 12-hour grace period, holding a 200-unit reservoir, rated IPX8 waterproof to five feet for 60 minutes, and controlled from an iOS or Android phone. Disposable changes do not require re-pairing the phone.

On the same day the company filed a 510(k) for 3D Intelligence, an updated dosing algorithm offering three selectable modes — Original, Optimized and Conservative — that it intends to ship on both the existing iLet (as iLet 3D, targeted for the end of 2026) and on Mint (as Mint 3D, targeted for the first-quarter 2027 launch). Both remain subject to FDA clearance; the algorithm is not cleared today.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement.” Sean Saint, President and CEO, Beta Bionics — 14 September 2026 announcement

Mint in four numbers

2ndcleared tubeless patch pump on the U.S. market

200 Uinsulin reservoir; 3-day wear plus a 12-hour grace period

1.5Mdisposable Mint units of capacity planned for 2027

Q1 2027full U.S. launch, pharmacy channel, ~40% of insured lives covered at launch

Figures from the 14 September 2026 announcement.

Two pieces, no charging, no carb counting

Beta Bionics built its business on the iLet Bionic Pancreas, an automated insulin delivery system whose adaptive closed-loop algorithm asks the user for body weight at setup and then doses without carbohydrate counting or manual basal rates. Mint takes that algorithm off the tubed pump and onto the body. Compatible sensors at clearance are Dexcom’s G7 and G7 15 Day and Abbott’s FreeStyle Libre 3 Plus; on the same morning, Senseonics announced a partnership to integrate its year-long implantable Eversense 365 CGM with the iLet, with commercial launch planned after integration work in the fourth quarter of 2026.

The company says Mint is smaller than the market-leading patch pump and, because the reusable half carries the electronics, the disposable half needs no battery to charge. Those are the company’s claims; head-to-head dimensions were not published in the release.

Three things that make Mint different

01

No carb counting

The iLet algorithm asks for body weight at setup and then decides every dose itself — the same adaptive closed loop that FDA cleared on the iLet in 2023, now on a patch. Sixty-nine percent of the company’s new users in the second quarter came straight from injections.

02

Two pieces, no charging

The electronics live in a reusable half; the disposable patch carries no battery to recharge and swaps without re-pairing the phone. Rated IPX8, controlled from iOS or Android.

03

Sold like a prescription

Mint launches through the pharmacy channel only, covering roughly 40% of insured U.S. lives at launch and at least 50% within a year, on the company’s figures — the model that took its pharmacy revenue up 153% year on year in Q2.

The $5 billion category Mint walks into

Mint enters the fastest-growing corner of insulin delivery. Tubeless patch pumps have been a one-company category in the United States since Omnipod, and the incumbent’s own results show what that category is worth: Insulet booked $2.7 billion of Omnipod revenue in 2025, up 31.6%, its tenth straight year of growth above 20%. Tandem, with its small tubed Mobi, passed $1 billion in sales the same year. Published forecasts for patch pumps sit well below those numbers, which says more about how narrowly the analysts draw the category than about its size.

Insulin patch pumps, sized to 2030

$1.56B → $2.55B

Insulin patch pumps, 2025 to 2030, as forecast by The Business Research Company (February 2026), compared with the category leader’s actual 2025 sales.

2025$1.56B

2026$1.73B

2030$2.55B

Insulet, 2025 actual$2.70B

Sources: The Business Research Company, Insulin Patch Pumps Global Market Report 2026 · Insulet, full-year 2025 results

Regulatory News outlook

We expect U.S. and international tubeless patch-pump sales to pass $5 billion a year by 2030, with a second cleared platform taking a meaningful minority of new starts rather than displacing the leader.

How we got here: Insulet’s $2.7 billion of 2025 Omnipod revenue compounded at 14% a year — less than half its current growth rate — reaches $5.2 billion in 2030 before any second entrant is counted; we treat the published $2.55 billion figure as a floor because it is already below the leader’s 2025 sales.

Mint against the pumps it will meet

Product	Form	Reservoir	Wear per fill	Dosing algorithm	U.S. clearance
Mint (Beta Bionics)	Tubeless patch; reusable + disposable	200 U	3 days + 12 h grace	iLet adaptive closed loop, no carb counting (3D Intelligence under review)	September 2026
Omnipod 5 (Insulet)	Tubeless patch; fully disposable pod	200 U	Up to 3 days	SmartAdjust with user carb entry	2022
Tandem Mobi	Compact tubed pump, short infusion set	200 U	Set changed every 2–3 days	Control-IQ	2023
MiniMed 780G (Medtronic)	Tubed pump	300 U	Set changed every 2–3 days (7-day set available)	SmartGuard with meal detection	2023

From each company’s labelling and announcements; not a clinical comparison.

What Q1 2027 needs to go right

Patch pumps are where automated insulin delivery is growing fastest, and until now a prescriber choosing a tubeless system had one manufacturer to choose from. A second cleared platform — with a different algorithm philosophy and a pharmacy-channel model — changes the competitive map for endocrinology practices, payers and the CGM makers whose sensors these pumps depend on. Leerink Partners analyst Mike Kratky told MedTech Dive the clearance “should help level the playing field.”

For regulatory readers the sequencing is the instructive part: the hardware cleared first, and the algorithm that will differentiate it is on its own 510(k) track. Beta Bionics is therefore launching a cleared device while an uncleared software version is in review — a common pattern in automated insulin delivery, and one that keeps launch timing hostage to a second decision.

• Full U.S. launch: first quarter of 2027, exclusively through the pharmacy channel, which the company says covers roughly 40% of insured U.S. lives at launch and is expected to reach at least 50% within the first year.
• Capacity: at least 1.5 million disposable Mint units planned for 2027.
• 3D Intelligence: 510(k) under review; iLet 3D targeted for the end of 2026 and Mint 3D for the Mint launch, both subject to clearance.
• Guidance: 2026 revenue guidance was revised to $121–126 million from $131–136 million, which the company attributed to prospective iLet users waiting for Mint.

What is not yet public: the cleared 510(k) number and the labelled age and diabetes-type indication for Mint, which the release does not state. FDA’s 510(k) database typically indexes a clearance within days; we will update this page when the record appears.

Frequently asked questions

What did FDA clear for Beta Bionics?

Mint, a tubeless insulin patch pump with a reusable component and a three-day disposable patch (plus a 12-hour grace period), a 200-unit reservoir, IPX8 waterproofing and smartphone control. The clearance was announced on 14 September 2026.

Is the 3D Intelligence algorithm cleared?

No. Beta Bionics submitted 3D Intelligence to FDA in a 510(k) on the same day. It plans iLet 3D by the end of 2026 and Mint 3D with the Mint launch in the first quarter of 2027, both subject to clearance.

When will Mint be available?

A full U.S. launch is planned for the first quarter of 2027, through the pharmacy channel only. The company plans capacity of at least 1.5 million disposable units in 2027.

Which CGMs work with Mint?

Dexcom G7, Dexcom G7 15 Day and Abbott FreeStyle Libre 3 Plus at clearance. Senseonics announced a separate integration of its Eversense 365 implantable sensor with the iLet.